本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Cytek BioSciences

5.29
-0.2100-3.82%
盘后5.390.1000+1.89%17:35 EST
成交量:483.53万
成交额:2,690.05万
市值:6.76亿
市盈率:-49.18
高:6.18
开:6.18
低:5.21
收:5.50
52周最高:7.30
52周最低:2.37
股本:1.28亿
流通股本:1.09亿
量比:1.98
换手率:4.44%
股息:- -
股息率:- -
每股收益(TTM):-0.1076
每股收益(LYR):-0.0461
净资产收益率:-3.36%
总资产收益率:-4.36%
市净率:1.79
市盈率(LYR):-114.78

数据加载中...

2022/03/14

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/03/02

重要事件披露

8-K - Current report
2022/02/28

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/02/23

重要事件披露

8-K - Current report
2022/02/17

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/02/14

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/02/14

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/02/14

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/01/06

重要事件披露

8-K - Current report
2021/09/02

季度报告

Cytek Biosciences, Inc.
2021/07/29

持股变动声明

4 - Statement of changes in beneficial ownership of securities
2021/07/27

重要事件披露

8-K - Current report
2021/07/27

持股变动声明

4 - Statement of changes in beneficial ownership of securities
2021/07/27

持股变动声明

4 - Statement of changes in beneficial ownership of securities
2021/07/23

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2021/07/20

SEC问询函

CORRESP [Cover] - Correspondence
2021/07/19

[修订]招股说明书

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
2021/07/14

[修订]招股说明书

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
2021/07/13

SEC问询函

CORRESP [Cover] - Correspondence
2021/07/02

SEC问询函

CORRESP [Cover] - Correspondence